HUTCHMED (China) Limited

Welcome everyone. Thank you for joining Hachmed 2026 interim results announcement and presentation. Before we start, I would just like to go over the safe harbors statement and disclaimer on page two. The performance and results of operation of Hachmed Group contained within this presentation are historical in nature and past performance is no guarantee of future results. Next, I would like to invite our Acting CEO and CFO, Johnny Chan, to start the opening. Johnny?

Okay, thank you, David. And welcome everyone again, joining our interim results webcast tonight. Together with me, we have our Deputy CFO, Lorenzo Zhou, also our George Yuan, Head of Commercial and also our Dr. Dai, Head of Discovery and Global Portfolio Management. All of us will be sharing with you our first half results and outlook. So on page four, as you can all see, we have achieved a lot in the first half. China product sales have very strong results, especially Elinate and Solenda, which grew by over 40%. Fusecla global in-market sales were strong, Ex-US markets were up 70% after rapid geographic expansion. On the bottom left, we have received two approved label expansions. Fluquitinib for RCC and Savolitinib for GC. In addition, we have three NDAs in China under priority review. On the top right, our next wave of innovation focuses on ATTCs. We have two first-in-class assets which have entered the Phase 1 clinical trials. A third asset, HMPL830, has cleared its IND and will be entering the clinic in the second half. At the same time, the Global Cephron Study and the China Sanovo Study will have their data readouts in the second half. I will now hand it over to Lorenzo Zhou, our Deputy CFO, to discuss our financial results.

Thank you, Johnny. On slide number six, I'd like to give more details of our financials for the first half of 2026. First of all, our oncology revenue was 162 million, including 121 million products revenue. This represents and about 23% growth over the first half of 2025. Johnny already mentioned our China product sales have shown a very good performance in the first half, but I'd like to highlight that XChina demand for recycler continues to grow as well, achieving an overall 40% growth in in-market sales. With this first half result, our full year guidance remains in the range of 330 million to 450 million. All together with other adventures revenue, the total group revenue amounted to 278 million. Next, please. On R&D expenses, which amounted to $279 million for the first half, compared to $72 million for the first half of 2025, the increase reflects on one thing, we initiate the global phase one trials of our ATTC assets, including 251 and 580. In addition, we increase our investments in our discovery capabilities, including our talents and AI. On the bottom line, we continue to be profitable with net income of $16 million. It is important to note in last years, we have included a $460 million SHPR divestment gain and also the share of the post-divestments, about $21 million. With this strong operating results and cash flows, we continue to have a very good cash reserve of $1.4 billion. Now, I'd like to hand over to Mr. George, our Head of Commercials, to give an update of our China commercials.